Jan 15, 2026
Insights, partnerships, and milestones shaping the future of translational and clinical development.
For Biovivium, progress has always meant more than strategy alone. It means building the right infrastructure around science so promising ideas can move forward without unnecessary friction.
As our work across translational and early clinical programs has expanded, one need continued to surface: access to high-quality primary cells and analytical support, processed quickly and handled by teams that understand downstream impact. That is why Biovivium has partnered with LabRat Consulting.
Over the past several years, LabRat has built a mobile, site-based processing platform capable of handling sensitive biological materials within minutes of collection. This approach meaningfully improves sample quality and reproducibility, particularly for time-sensitive and cell-based programs.
Together, we now support:
Disease-state primary cells for discovery and target validation
Stem cells for regenerative medicine programs
Immune cells from oncology and autoimmune indications
Blood-derived materials supporting translational research
In parallel, analytical capabilities include:
Flow cytometry
DNA and RNA preparation for PCR and sequencing
LabRat Consulting serves as Biovivium’s preferred partner for preclinical materials and analytical support, supporting Biovivium-led programs and external partner initiatives.
This partnership reflects shared values, complementary expertise, and a practical understanding of how science moves from idea to clinic.
Partnering with LabRat Consulting allows us to meaningfully expand the support we provide to our clients, particularly in programs where sample quality, speed, and translational integrity are critical.
— George Lott, CEO, Biovivium Strategies
Biovivium exists to bridge pioneering science with real-world clinical development. With LabRat Consulting, that bridge is stronger, faster, and built to scale.